Point72 Asset Management L.P. Makes New Investment in OrthoPediatrics Corp. (NASDAQ:KIDS)

Point72 Asset Management L.P. bought a new stake in shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund bought 321,405 shares of the company's stock, valued at approximately $7,450,000. Point72 Asset Management L.P. owned 1.33% of OrthoPediatrics as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Millennium Management LLC acquired a new position in OrthoPediatrics during the fourth quarter worth $9,798,000. Wasatch Advisors LP grew its position in OrthoPediatrics by 47.2% during the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock valued at $16,141,000 after buying an additional 223,217 shares during the period. Wellington Management Group LLP grew its position in OrthoPediatrics by 20.2% during the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after buying an additional 178,078 shares during the period. Dimensional Fund Advisors LP boosted its position in OrthoPediatrics by 29.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock worth $15,576,000 after purchasing an additional 152,681 shares during the period. Finally, Kennedy Capital Management LLC boosted its position in OrthoPediatrics by 129.8% during the fourth quarter. Kennedy Capital Management LLC now owns 249,978 shares of the company's stock worth $5,794,000 after purchasing an additional 141,174 shares during the period. Institutional investors and hedge funds own 69.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KIDS. Lake Street Capital began coverage on shares of OrthoPediatrics in a research report on Monday, April 7th. They issued a "buy" rating and a $37.00 price objective for the company. Stifel Nicolaus decreased their price target on shares of OrthoPediatrics from $40.00 to $32.00 and set a "buy" rating on the stock in a research note on Wednesday, March 5th. Needham & Company LLC reaffirmed a "buy" rating and issued a $42.00 target price on shares of OrthoPediatrics in a research note on Thursday, May 8th. Truist Financial cut their price target on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Piper Sandler dropped their target price on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $35.83.

OrthoPediatrics Stock Performance

Shares of NASDAQ KIDS traded down $0.32 during midday trading on Friday, hitting $20.83. 72,124 shares of the company's stock traded hands, compared to its average volume of 196,893. OrthoPediatrics Corp. has a 1 year low of $20.25 and a 1 year high of $35.99. The stock has a market capitalization of $505.90 million, a price-to-earnings ratio of -16.93 and a beta of 1.09. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.68 and a current ratio of 7.17. The firm has a fifty day moving average of $22.54 and a 200 day moving average of $23.71.

OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.13). The firm had revenue of $52.41 million during the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. On average, analysts forecast that OrthoPediatrics Corp. will post -0.93 earnings per share for the current year.

Insider Activity

In related news, CEO David R. Bailey sold 6,620 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $164,573.20. Following the transaction, the chief executive officer now owns 319,155 shares of the company's stock, valued at $7,934,193.30. This trade represents a 2.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Gregory A. Odle sold 5,359 shares of the firm's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $133,224.74. Following the completion of the transaction, the insider now directly owns 148,788 shares in the company, valued at $3,698,869.68. This represents a 3.48% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 23,732 shares of company stock worth $589,978. 32.70% of the stock is currently owned by insiders.

OrthoPediatrics Profile

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.